GSK Partners With Myogen Ahead Of Ambrisentan Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will commercialize Myogen’s selective endothelin receptor antagonist for pulmonary arterial hypertension outside the U.S. following approval; Myogen will take over marketing of GSK’s Flolan in the U.S.